The article highlights a study that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). It discusses thatAn analysis of the baseline characteristics showed that 65 percent of the patients had DLBCL or PMBCL.